Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000119312511039250/d10k.htm
Exhibit 99.1
Contacts:
| Alexion Pharmaceuticals, Inc. Irving Adler Sr. Director, Corporate Communications (203) 271-8210 |
Makovksy + Company (Media) Kristie Kuhl (212) 508-9642 |
Rx Communications (Investors) Rhonda Chiger (917) 322-2569 |
Alexion Reports Fourth Quarter and Full Year 2010 Results
- Soliris® Net Product Sales Increased 40 Percent to $541 Million in 2010 –
- Continued Strong Uptake of Soliris by New Patients in Core Territories: U.S., Western Europe and Japan –
- aHUS and Transplant Programs Advance –
- Taligen and Orphatec Acquisitions Expand Rare Disease Pipeline -
Fourth Quarter 2010 Financial Highlights:
| • | Q4 2010 net product sales increased 41 percent to $156.0 million, compared to $110.6 million in Q4 2009. |
| • | Q4 2010 GAAP net income was $26.5 million, or $0.28 per share, compared to Q4 2009 GAAP net income of $237.1 million, or $2.59 per share, which included a non-recurring tax benefit of $215.5 million, or $2.36 per share. |
| • | Q4 2010 non-GAAP net income increased 71 percent to $48.6 million, or $0.51 per share, compared to Q4 2009 non-GAAP net income of $28.5 million, or $0.31 per share. |
Full-Year 2010 Financial Highlights:
| • | 2010 net product sales increased 40 percent to $541.0 million, compared to $386.8 million in 2009. |
| • | 2010 GAAP net income was $97.0 million, or $1.04 per share, compared to 2009 GAAP net income of $295.2 million, or $3.26 per share, which included a non-recurring tax benefit of $215.5 million, or $2.38 per share. |
| • | 2010 non-GAAP net income increased 54 percent to $167.3 million, or $1.78 per share, compared to 2009 non-GAAP net income of $108.4 million, or $1.18 per share. |
CHESHIRE, Conn., February 10, 2011 — Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2010. For the three
The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 10, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
ALXN Annual Reports
- 10-K Annual Report February 2020
- 10-K Annual Report February 2019
- 10-K Annual Report February 2018
- 10-K Annual Report February 2017
- 10-K Annual Report February 2016
- 10-K Annual Report February 2015
- 10-K Annual Report February 2014
- 10-K Annual Report February 2013
- 10-K Annual Report February 2012
-
10-K Annual Report February 2011
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0001193125-11-039250
Submitted to the SEC: Thu Feb 17 2011 5:17:01 PM EST
Accepted by the SEC: Thu Feb 17 2011
Period: Friday, December 31, 2010
Industry: Pharmaceutical Preparations
External Resources:
Insider Transactions
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/alxn/0001193125-11-039250.htm
